The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback